Ernexa Therapeutics Inc. (ERNA) Stock Price & Analysis

Ernexa Therapeutics Inc. (ERNA) fell 1.50% to USD 3.93 as of July 25, 2026 at 22:04 UTC, according to Nexqual real-time market data.

ERNA last closed at USD 3.99; the session ranged USD 3.91–4.2 on volume of 29,834 shares. Market capitalization is $4.58M, with a 52-week range of USD 3.18–71.5 (NCM). Source: Nexqual, July 25, 2026 at 22:04 UTC.

Key Statistics (as of July 25, 2026 at 22:04 UTC)

Technical Analysis (ERNA)

Nexqual's technical model rates ERNA "SELL" based on 3 bullish and 5 bearish signals across 125 daily candles, as of July 25, 2026 at 22:04 UTC.

Analyst Ratings (ERNA)

Wall Street analysts rate ERNA "None" based on 1 analysts, with a mean price target of USD 30 (range USD 30–30), per Nexqual as of July 25, 2026 at 22:04 UTC.

Earnings (ERNA)

Recent Earnings History

Source: Nexqual, July 25, 2026 at 22:04 UTC.

Financials & Fundamentals (ERNA)

Source: Nexqual, July 25, 2026 at 22:04 UTC.

Financial Health Score (ERNA)

Nexqual rates Ernexa Therapeutics Inc.'s overall financial health "Mixed" across five dimensions, as of July 25, 2026 at 22:04 UTC.

Ownership (ERNA)

Source: Nexqual, July 25, 2026 at 22:04 UTC.

Leadership (ERNA)

Ernexa Therapeutics Inc. is led by Sanjeev Luther (age 63), CEO, President & Director, per Nexqual as of July 25, 2026 at 22:04 UTC.

Major Backers & Investors (ERNA)

Notable institutional backers of Ernexa Therapeutics Inc. include Bleichroeder LP, Dauntless Investment Group, LLC , Corient Private Wealth LLC, according to Nexqual as of July 25, 2026 at 22:04 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, July 25, 2026 at 22:04 UTC.

From Ernexa Therapeutics Inc.'s Latest SEC 10-K Filing (filed 2026-03-13)

Key Strengths & Strategy (as disclosed to the SEC)

• The legal systems of certain countries, particularly certain developing countries including India and China, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology and pharmaceutical products, which could make it difficult for us to stop the infringement of our in-licensed patents or marketing of competing products in violation of our proprietary rights generally.
• The FDA typically conducts a review of proposed proprietary product names, including an evaluation of potential for confusion with other product names.
• If the FDA (or an equivalent administrative body in a foreign jurisdiction) objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe the existing rights of third parties, and be acceptable to the FDA.
• Although we seek such protection in part by entering into confidentiality agreements with our vendors, employees, consultants and others who may have access to proprietary information, we cannot be certain that these agreements will not be breached, adequate remedies for any breach would be available, or our trade secrets, know-how and other unpatented proprietary technology will not otherwise become known to or be independently developed by our competitors.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 22:04 UTC. This page is informational and not investment advice.